Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 143-150, May 2011

Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus☆☆☆

  • Lizheng Shi

      Affiliations

    • School of Public Health and Tropical Medicine, Tulane University
    • School of Medicine, Tulane University
    • Southeast Louisiana Veterans Health Care System
    • Corresponding Author InformationCorresponding author. School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 1900, Tulane University, New Orleans, LA 70112. Tel.: +1 504 988 6548.
    • ,
  • Yingnan Zhao

      Affiliations

    • School of Public Health and Tropical Medicine, Tulane University
    • Southeast Louisiana Veterans Health Care System
    • ,
  • Keith Szymanski

      Affiliations

    • Takeda Pharmaceuticals America, USA
    • ,
  • Lillian Yau

      Affiliations

    • School of Public Health and Tropical Medicine, Tulane University
    • Southeast Louisiana Veterans Health Care System
    • ,
  • Vivian Fonseca

      Affiliations

    • School of Medicine, Tulane University
    • Southeast Louisiana Veterans Health Care System

Received 23 February 2010; received in revised form 9 May 2010; accepted 23 June 2010. published online 13 August 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Shi, Yau, Fonseca, and Zhao are also WOC employees/investigators for the Southeast Louisiana Veterans Health Care System. Shi has received research support (to Tulane) from Eli Lilly, Takeda, and Blue Cross Blue Shield of Louisiana. Fonseca has received research support (to Tulane) from GlaxoSmithKline, Novartis, Novo-Nordisk, Takeda, Astra-Zeneca, Pfizer, Sanofi- Aventis, Eli Lilly, Daiichi-Sankyo, National Institutes of Health, and the American Diabetes Association; Fonseca has also received honoraria for consulting and lectures from GlaxoSmithKline, Novartis, Takeda, Novo-Nordisk, Sanofi- Aventis, Eli Lilly, and Daiichi Sankyo. Fonseca is currently the chair of a data monitoring committee for a clinical trial sponsored by Takeda. Dr. Keith Szymanski is a clinical science and outcomes manager in the medical affairs division of Takeda Pharmaceuticals North America, Inc.

☆☆ Data analysis was performed primarily by Ms. Zhao, and data interpretation was performed by all authors. Drs. Shi and Fonseca wrote the manuscript with assistance from Dr. Szymanski. All authors contributed to the revisions of the manuscript.

PII: S1056-8727(10)00068-1

doi:10.1016/j.jdiacomp.2010.06.003

Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 143-150, May 2011

Article Tools

* Image Usage & Resolution